መነሻ › Multiple Myeloma › ሚኔሶታ
በሚኔሶታ ለMultiple Myeloma የሚደረጉ ክሊኒካዊ ጥናቶች
ለMultiple Myeloma የሚደረጉ 30 ጥናቶች በሚኔሶታ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በሚኔሶታ ውስጥ ያሉ ከተሞች
Official study text (English)
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Mayo Clinic Health System-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
ተሳታዮችን በመፈለግ ላይ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06630104SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
- Mayo Clinic in Rochester, Rochester
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07850284A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- University Of Minnesota Medical Center, Minneapolis
- Mayo Clinic, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07258511A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Mayo Clinic, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07393282A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mayo Clinic Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05201781A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Minnesota Oncology - Minneapolis Clinic /ID# 278720, Minneapolis
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07095452Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Minnesota, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06297226Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT06375044Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT06940297Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Minnesota Oncology Hematology PA-Chaska, Chaska
- እና 24 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ኦገስ 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Mayo Clinic - Transplant Center - Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ኦገስ 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Minneapolis
- Research Site, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT05850234A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Minnesota, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Rochester, Minnesota, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጁላይ 2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic - Rochester /ID# 251164, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Mayo Clinic, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ጁላይ 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Riverwood Healthcare Center, Aitkin
- Essentia Health-St. Joseph's Medical Center, Brainerd
- Essentia Health - Duluth Clinic, Duluth
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ19 እስከ 110 · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁን 2026 · NCT02012699Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁን 2026 · NCT06785415Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
ተሳታዮችን በመፈለግ ላይደረጃ 2
እስከ እድሜ 60 · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁን 2026 · NCT03314974Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Riverwood Healthcare Center, Aitkin
- Essentia Health - Baxter Clinic, Baxter
- Sanford Joe Lueken Cancer Center, Bemidji
- እና 40 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ10 ጁን 2026 · NCT05561387A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ጁን 2026 · NCT03017820Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- University of Minnesota - Masonic Cancer Center, Minneapolis
ተሳታዮችን በመፈለግ ላይ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ጁን 2026 · NCT03858205Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Minnesota Oncology Hematology, Minneapolis
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ኤፕሪ 2026 · NCT05972135Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
- Mayo Clinic in Rochester, Rochester
ተሳታዮችን በመፈለግ ላይ
እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ኤፕሪ 2026 · NCT06145581cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ 40 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ጃንዩ 2026 · NCT05366881Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ14 ኦክቶ 2025 · NCT00626496IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- University of Minnesota, Minneapolis
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ጁን 2025 · NCT06119685Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- Center for International Blood and Marrow Transplant Research, Minneapolis
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኦገስ 2023 · NCT03127761ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።